Review
doi: 10.4103/0973-1482.172575.
Sunitinib-induced thrombotic microangiopathy
Affiliations
- PMID: 27072203
- DOI: 10.4103/0973-1482.172575
Item in Clipboard
Review
Sunitinib-induced thrombotic microangiopathy
J Cancer Res Ther.
2016 Jan-Mar.
Free article
Abstract
Sunitinib-induced thrombotic microangiopathy (TMA) is a secondary TMA caused by sunitinib. Despite the extensive use of sunitinib in patients with renal cell carcinoma and other malignancies, little is known about this complication of sunitinib. No clinical trials of sunitinib have studied this complication in any group of patients. We here review the normal physiology of vascular endothelial growth factor in the kidney, and discuss the pathogenesis, clinical and laboratory manifestations, pathological changes in the kidney, and the management of this uncommon complication of sunitinib.
Similar articles
-
Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy.Nephrol Dial Transplant. 2010 Mar;25(3):1001-3. doi: 10.1093/ndt/gfp666. Epub 2009 Dec 16. Nephrol Dial Transplant. 2010. PMID: 20019017
-
Sunitinib-associated thrombotic microangiopathy: a significant risk.Clin Oncol (R Coll Radiol). 2014 Aug;26(8):515. doi: 10.1016/j.clon.2014.03.010. Epub 2014 Apr 18. Clin Oncol (R Coll Radiol). 2014. PMID: 24746506 No abstract available.
-
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.Nephrol Dial Transplant. 2009 Feb;24(2):682-5. doi: 10.1093/ndt/gfn657. Epub 2008 Dec 2. Nephrol Dial Transplant. 2009. PMID: 19054798
-
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.Hum Pathol. 2014 Sep;45(9):1918-27. doi: 10.1016/j.humpath.2014.05.015. Epub 2014 Jun 12. Hum Pathol. 2014. PMID: 25087655 Review.
-
Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.J Oncol Pharm Pract. 2007 Mar;13(1):5-15. doi: 10.1177/1078155207077924. J Oncol Pharm Pract. 2007. PMID: 17621562 Review.
Cited by
-
An Interesting Case: Sunitinib-Induced Microangiopathic Hemolytic Anemia and Nephrotic Syndrome.Turk J Haematol. 2021 Jun 1;38(2):163-165. doi: 10.4274/tjh.galenos.2020.2020.0532. Epub 2020 Oct 30. Turk J Haematol. 2021. PMID: 33121226 Free PMC article. No abstract available.
-
Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy.BMJ Case Rep. 2024 Jan 5;17(1):e255841. doi: 10.1136/bcr-2023-255841. BMJ Case Rep. 2024. PMID: 38182165 Free PMC article.
-
An Update in Drug-Induced Thrombotic Microangiopathy.Front Med (Lausanne). 2020 May 22;7:212. doi: 10.3389/fmed.2020.00212. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32528969 Free PMC article. No abstract available.
-
Kidney Toxicity of Drugs for the Heart: An Updated Perspective.Metabolites. 2025 Mar 11;15(3):191. doi: 10.3390/metabo15030191. Metabolites. 2025. PMID: 40137155 Free PMC article. Review.
-
A Case of Acute Kidney Injury, Proteinuria, and Thrombotic Microangiopathy Associated With Sunitinib Therapy in Metastatic Pancreatic Neuroendocrine Tumor.Cureus. 2024 Mar 21;16(3):e56660. doi: 10.7759/cureus.56660. eCollection 2024 Mar. Cureus. 2024. PMID: 38646245 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
